Virulence factors in brucellosis: implications for aetiopathogenesis and treatment | Expert Reviews in Molecular Medicine | Cambridge Core (original) (raw)

Abstract

Brucella species are responsible for the global zoonotic disease brucellosis. These intracellular pathogens express a set of factors – including lipopolysaccharides, virulence regulator proteins and phosphatidylcholine – to ensure their full virulence. Some virulence factors are essential for invasion of the host cell, whereas others are crucial to avoid elimination by the host. They allow Brucella spp. to survive and proliferate within its replicative vacuole and enable the bacteria to escape detection by the host immune system. Several strategies have been used to develop animal vaccines against brucellosis, but no adequate vaccine yet exists to cure the disease in humans. This is probably due to the complicated pathophysiology of human Brucella spp. infection, which is different than in animal models. Here we review Brucella spp. virulence factors and how they control bacterial trafficking within the host cell.

References

1Bricker, B.J. et al. (2000) Molecular characterization of Brucella strains isolated from marine mammals. J Clin Microbiol 38, 1258-62CrossRef Google Scholar PubMed

2Nielsen, O. et al. (2001) Serologic survey of Brucella spp. antibodies in some marine mammals of North America. J Wildl Dis 37, 89-100CrossRef Google Scholar PubMed

5Boschiroli, M.L., Foulongne, V. and O'Callaghan, D. (2001) Brucellosis: a worldwide zoonosis. Curr Opin Microbiol 4, 58-64CrossRef Google Scholar PubMed

8Banai, M. (2002) Control of small ruminant brucellosis by use of Brucella melitensis Rev.1 vaccine: laboratory aspects and field observations. Vet Microbiol 90, 497-519CrossRef Google Scholar PubMed

9Blasco, J.M. and Diaz, R. (1993) Brucella melitensis Rev-1 vaccine as a cause of human brucellosis. Lancet 342, 805CrossRef Google Scholar PubMed

10Moriyon, I. et al. (2004) Rough vaccines in animal brucellosis: structural and genetic basis and present status. Vet Res 35, 1-38CrossRef Google Scholar PubMed

11Nicoletti, P. (1990) Vaccination against Brucella. Adv Biotechnol Processes 13, 147-168Google Scholar PubMed

12Young, E.J. et al. (2000) Thrombocytopenic purpura associated with brucellosis: report of 2 cases and literature review. Clin Infect Dis 31, 904-909CrossRef Google Scholar PubMed

13Celli, J. et al. (2003) Brucella evades macrophage killing via VirB-dependent sustained interactions with the endoplasmic reticulum. J Exp Med 198, 545-556CrossRef Google Scholar PubMed

14Liautard, J.P. et al. (1996) Interactions between professional phagocytes and Brucella spp. Microbiologia 12, 197-206Google Scholar PubMed

15Pizarro-Cerda, J. et al. (1998) Brucella abortus transits through the autophagic pathway and replicates in the endoplasmic reticulum of nonprofessional phagocytes. Infect Immun 66, 5711-5724CrossRef Google Scholar PubMed

16Pizarro-Cerda, J., Moreno, E. and Gorvel, J.P. (2000) Invasion and intracellular trafficking of Brucella abortus in nonphagocytic cells. Microbes Infect 2, 829-835CrossRef Google Scholar PubMed

17Delrue, R.M. et al. (2001) Identification of Brucella spp. genes involved in intracellular trafficking. Cell Microbiol 3, 487-497CrossRef Google Scholar PubMed

18Kohler, S. et al. (2003) What is the nature of the replicative niche of a stealthy bug named Brucella? Trends Microbiol 11, 215-219CrossRef Google Scholar PubMed

19Kohler, S. et al. (2002) The intramacrophagic environment of Brucella suis and bacterial response. Vet Microbiol 90, 299-309CrossRef Google Scholar PubMed

20Keleti, G., Feingold, D.S. and Youngner, J.S. (1974) Interferon induction in mice by lipopolysaccharide from Brucella abortus. Infect Immun 10, 282-283CrossRef Google Scholar PubMed

21Moreno, E., Berman, D.T. and Boettcher, L.A. (1981) Biological activities of Brucella abortus lipopolysaccharides. Infect Immun 31, 362-370CrossRef Google Scholar PubMed

22Goldstein, J. et al. (1992) Lipopolysaccharide (LPS) from Brucella abortus is less toxic than that from Escherichia coli, suggesting the possible use of B. abortus or LPS from B. abortus as a carrier in vaccines. Infect Immun 60, 1385-1389CrossRef Google Scholar PubMed

23Rasool, O. et al. (1992) Effect of Brucella abortus lipopolysaccharide on oxidative metabolism and lysozyme release by human neutrophils. Infect Immun 60, 1699-1702CrossRef Google Scholar PubMed

24Riley, L.K. and Robertson, D.C. (1984) Brucellacidal activity of human and bovine polymorphonuclear leukocyte granule extracts against smooth and rough strains of Brucella abortus. Infect Immun 46, 231-236CrossRef Google Scholar PubMed

25Lapaque, N. et al. (2006) Differential inductions of TNF-alpha and IGTP, IIGP by structurally diverse classic and non-classic lipopolysaccharides. Cell Microbiol 8, 401-413CrossRef Google Scholar PubMed

26Eisenschenk, F.C., Houle, J.J. and Hoffmann, E.M. (1999) Mechanism of serum resistance among Brucella abortus isolates. Vet Microbiol 68, 235-244CrossRef Google Scholar PubMed

27Martinez de Tejada, G. et al. (1995) The outer membranes of Brucella spp. are resistant to bactericidal cationic peptides. Infect Immun 63, 3054-3061CrossRef Google Scholar PubMed

28Freer, E. et al. (1996) Brucella-Salmonella lipopolysaccharide chimeras are less permeable to hydrophobic probes and more sensitive to cationic peptides and EDTA than are their native Brucella sp. counterparts. J Bacteriol 178, 5867-5876CrossRef Google Scholar PubMed

29Velasco, J. et al. (2000) Brucella abortus and its closest phylogenetic relative, Ochrobactrum spp., differ in outer membrane permeability and cationic peptide resistance. Infect Immun 68, 3210-3218CrossRef Google Scholar PubMed

30Sola-Landa, A. et al. (1998) A two-component regulatory system playing a critical role in plant pathogens and endosymbionts is present in Brucella abortus and controls cell invasion and virulence. Mol Microbiol 29, 125-138CrossRef Google Scholar PubMed

31Detilleux, P.G., Deyoe, B.L. and Cheville, N.F. (1990) Penetration and intracellular growth of Brucella abortus in nonphagocytic cells in vitro. Infect Immun 58, 2320-2328CrossRef Google Scholar PubMed

32Porte, F. et al. (2003) Role of the Brucella suis lipopolysaccharide O antigen in phagosomal genesis and in inhibition of phagosome-lysosome fusion in murine macrophages. Infect Immun 71, 1481-1490CrossRef Google Scholar PubMed

33Jimenez de Bagues, M.P. et al. (2004) Different responses of macrophages to smooth and rough Brucella spp.: relationship to virulence. Infect Immun 72, 2429-2433CrossRef Google Scholar PubMed

34Forestier, C. et al. (1999) Lysosomal accumulation and recycling of lipopolysaccharide to the cell surface of murine macrophages, an in vitro and in vivo study. J Immunol 162, 6784-6791CrossRef Google Scholar

35Forestier, C. et al. (1999) Interaction of Brucella abortus lipopolysaccharide with major histocompatibility complex class II molecules in B lymphocytes. Infect Immun 67, 4048-4054CrossRef Google Scholar PubMed

36Forestier, C. et al. (2000) Brucella abortus lipopolysaccharide in murine peritoneal macrophages acts as a down-regulator of T cell activation. J Immunol 165, 5202-5210CrossRef Google Scholar PubMed

37Guzman-Verri, C. et al. (2002) The two-component system BvrR/BvrS essential for Brucella abortus virulence regulates the expression of outer membrane proteins with counterparts in members of the Rhizobiaceae. Proc Natl Acad Sci U S A 99, 12375-12380CrossRef Google Scholar PubMed

38Lamontagne, J. et al. (2007) Extensive cell envelope modulation is associated with virulence in Brucella abortus. J Proteome Res 6, 1519-1529CrossRef Google Scholar PubMed

39Guzman-Verri, C. et al. (2001) GTPases of the Rho subfamily are required for Brucella abortus internalization in nonprofessional phagocytes: direct activation of Cdc42. J Biol Chem 276, 44435-44443CrossRef Google Scholar PubMed

40Manterola, L. et al. (2005) The lipopolysaccharide of Brucella abortus BvrS/BvrR mutants contains lipid A modifications and has higher affinity for bactericidal cationic peptides. J Bacteriol 187, 5631-5639CrossRef Google Scholar PubMed

41O'Callaghan, D. et al. (1999) A homologue of the Agrobacterium tumefaciens VirB and Bordetella pertussis Ptl type IV secretion systems is essential for intracellular survival of Brucella suis. Mol Microbiol 33, 1210-1220CrossRef Google Scholar PubMed

42Porte, F., Liautard, J.P. and Kohler, S. (1999) Early acidification of phagosomes containing Brucella suis is essential for intracellular survival in murine macrophages. Infect Immun 67, 4041-4047CrossRef Google Scholar PubMed

43Cascales, E. and Christie, P.J. (2003) The versatile bacterial type IV secretion systems. Nat Rev Microbiol 1, 137-149CrossRef Google Scholar PubMed

44Christie, P.J. (1997) Agrobacterium tumefaciens T-complex transport apparatus: a paradigm for a new family of multifunctional transporters in eubacteria. J Bacteriol 179, 3085-3094CrossRef Google Scholar PubMed

45Covacci, A. and Rappuoli, R. (1993) Pertussis toxin export requires accessory genes located downstream from the pertussis toxin operon. Mol Microbiol 8, 429-434CrossRef Google Scholar PubMed

46Bardill, J.P., Miller, J.L. and Vogel, J.P. (2005) IcmS-dependent translocation of SdeA into macrophages by the Legionella pneumophila type IV secretion system. Mol Microbiol 56, 90-103CrossRef Google Scholar PubMed

47Ward, D.V. et al. (2002) Peptide linkage mapping of the Agrobacterium tumefaciens vir-encoded type IV secretion system reveals protein subassemblies. Proc Natl Acad Sci U S A 99, 11493-11500CrossRef Google Scholar PubMed

48Comerci, D. J. et al. (2001) Essential role of the VirB machinery in the maturation of the Brucella abortus-containing vacuole. Cell Microbiol 3, 159-168CrossRef Google Scholar PubMed

49Kahl-McDonagh, M.M. et al. (2006) Evaluation of novel Brucella melitensis unmarked deletion mutants for safety and efficacy in the goat model of brucellosis. Vaccine 24, 5169-5177CrossRef Google Scholar PubMed

50Arellano-Reynoso, B. et al. (2005) Cyclic beta-1,2-glucan is a Brucella virulence factor required for intracellular survival. Nat Immunol 6, 618-625CrossRef Google Scholar PubMed

51de Iannino, N.I. et al. (2000) Osmotic regulation of cyclic 1,2-beta-glucan synthesis. Microbiology 146, 1735-1742CrossRef Google Scholar PubMed

52Briones, G. et al. (2001) Brucella abortus cyclic beta-1,2-glucan mutants have reduced virulence in mice and are defective in intracellular replication in HeLa cells. Infect Immun 69, 4528-4535CrossRef Google Scholar PubMed

54Conde-Alvarez, R. et al. (2006) Synthesis of phosphatidylcholine, a typical eukaryotic phospholipid, is necessary for full virulence of the intracellular bacterial parasite Brucella abortus. Cell Microbiol 8, 1322-1335CrossRef Google Scholar PubMed

55Navarro, E. et al. (2006) Use of real-time quantitative polymerase chain reaction to monitor the evolution of Brucella melitensis DNA load during therapy and post-therapy follow-up in patients with brucellosis. Clin Infect Dis 42, 1266-1273CrossRef Google Scholar PubMed

56Pappas, G., Akritidis, N. and Tsianos, E. (2005) Effective treatments in the management of brucellosis. Expert Opin Pharmacother 6, 201-209CrossRef Google Scholar PubMed

57Solera, J. et al. (2004) A randomized, double-blind study to assess the optimal duration of doxycycline treatment for human brucellosis. Clin Infect Dis 39, 1776-1782CrossRef Google Scholar PubMed

58Al Dahouk, S. et al. (2005) Failure of a short-term antibiotic therapy for human brucellosis using ciprofloxacin. A study on in vitro susceptibility of Brucella strains. Chemotherapy 51, 352-356CrossRef Google Scholar

59Al-Mariri, A. et al. (2001) Induction of immune response in BALB/c mice with a DNA vaccine encoding bacterioferritin or P39 of Brucella spp. Infect Immun 69, 6264-6270CrossRef Google Scholar PubMed

60Cassataro, J. et al. (2007) A DNA vaccine coding for the chimera BLSOmp31 induced a better degree of protection against B. ovis and a similar degree of protection against B. melitensis than Rev.1 vaccination. Vaccine 25, 5958-5967CrossRef Google Scholar

61Cassataro, J. et al. (2005) A DNA vaccine coding for the Brucella outer membrane protein 31 confers protection against B. melitensis and B. ovis infection by eliciting a specific cytotoxic response. Infect Immun 73, 6537-6546CrossRef Google Scholar

62Munoz-Montesino, C. et al. (2004) Intraspleen delivery of a DNA vaccine coding for superoxide dismutase (SOD) of Brucella abortus induces SOD-specific CD4+ and CD8+ T cells. Infect Immun 72, 2081-2087CrossRef Google Scholar PubMed

63Yu, D.H., Hu, X.D. and Cai, H. (2007) A combined DNA vaccine encoding BCSP31, SOD, and L7/L12 confers high protection against Brucella abortus 2308 by inducing specific CTL responses. DNA Cell Biol 26, 435-443CrossRef Google Scholar PubMed

Gorvel, J.P., ed. (2003) Intracellular Pathogens in Membrane Interactions and Vacuole Biogenesis, Landes Bioscience/Eurekah.comCrossRef Google Scholar